Anti-GD2 Monoclonal Antibodies in Patients With R/R HRNB: Pivotal Clinical Trials


Drs Sholler and Agrawal detail recent studies on naxitamab and dinutuximab demonstrating effectiveness in treating recurrent or refractory neuroblastoma, leading to their FDA approvals, and significantly influencing treatment practices.

Related Videos
Expert on ovarian cancer
Expert on ovarian cancer
Related Content